منابع مشابه
Boldly going where no one has gone before.
With all the changes occurring in the U.S. health care system come new opportunities for physician executives willing to boldly go where no one has gone before. These positions are being newly created and thus are somewhat undefined and uncharted. Health care organizations want individuals for high-risk positions with unique skill sets and bright, new ideas. Organizations want to find people wh...
متن کاملGoing down first class.
should be able to go straight into general practice: he will certainly be medically well educated for this. Nevertheless, the goodwill of local doctors would be of paramount importance if he is to be successful, and this seems unlikely in the present competitive society. At this stage, therefore, I would counsel caution to those British graduates who might consider emigration to France. On the ...
متن کاملARVs: The Next Generation. Going Boldly Together to New Frontiers of HIV Treatment
New antiretrovirals (ARVs), particularly the potentially ‘‘game-changing’’ ARV dolutegravir, offer major potential to meet the compelling need for simpler and better HIV treatment for tens of millions of people in the coming decade. Advantages include substantially lower manufacturing cost, fewer side effects, and less risk of resistance. But key obstacles must be addressed in order to develop ...
متن کاملCosmic Lithium: Going up or Coming Down?
Observations of interstellar lithium provide a valuable complement to studies of lithium in Pop I and Pop II stars. Large corrections for unseen LiII and for non-gas phase lithium have provided obstacles to using interstellar data for abundance determinations. An approach to surmounting these difficulties is proposed and is applied to the Galaxy and the LMC. The key is that since potassium and ...
متن کاملBoldly Targeting Kinases without mutations.
and those arising in the context of viral infections remains to be elucidated. These entities share with MBL the indolent course and the low propensity to progress to overt malignancy. Among the patients followed for 5 years, only 17% of them progressed to clinically overt, splenic B-cell lymphoma of MZ origin, and only 3 needed treatment over the follow-up time. It is likely that CBL-MZ repres...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Neuroscience
سال: 2006
ISSN: 1097-6256
DOI: 10.1038/nn0406-474